Purpose/Objective: Curative (chemo-) radiation for head and neck cancer (HNC) may result in severe acute and late side effects, including tube feeding dependence. The purpose of this multicenter prospective cohort study was to develop a multivariate prediction model for tube feeding dependence 6 months (TUBE M6 ) after curative primary RT (radiotherapy), BioRT (radiotherapy + cetuximab) or CHRT (radiotherapy + chemotherapy) for head and neck cancer based on pre-treatment and treatment characteristics (including dose volume parameters) that can be used to select patients for radiotherapy treatment plan optimization.
Purpose/Objective: Curative (chemo-) radiation for head and neck cancer (HNC) may result in severe acute and late side effects, including tube feeding dependence. The purpose of this multicenter prospective cohort study was to develop a multivariate prediction model for tube feeding dependence 6 months (TUBE M6 ) after curative primary RT (radiotherapy), BioRT (radiotherapy + cetuximab) or CHRT (radiotherapy + chemotherapy) for head and neck cancer based on pre-treatment and treatment characteristics (including dose volume parameters) that can be used to select patients for radiotherapy treatment plan optimization. Materials and Methods: The study included 416 patients with HNC. In all patients, TUBE M6 was scored prospectively in a standardized followup program. To design the prediction model, the penalized learning method LASSO was used, with TUBE M6 as the primary endpoint. Results: The incidence of TUBE M6 was 9.9% (41 out of 416 patients). Using the LASSO-parameter selection procedure, the multivariate model with the best model performance was selected, consisting of the following variables: male sex, advanced T-stage (T3-T4), moderate and severe weight loss at baseline, baseline CTCAE dysphagia-score, accelerated RT, CHRT, BioRT, the mean dose to the superior and inferior pharyngeal constrictor muscle (PCM), mean dose to the contralateral parotid gland and the mean dose to the cricopharyngeal muscle (CM) (see :Table) . Model performance at internal validation in terms of area under the curve was 0.90 in double cross validation, while the prediction model scored excellent using other performance measures. Of the four dose-volume parameters, the mean dose to the PCM superior was most important. In the graph (see: Figure) an example of the predicted NTCP value for TUBE M6 as a function of the mean dose to the PCM superior is shown for a female patient with a T3-T4 tumor, with severe weight loss and dysphagia prior to the start of chemoradiotherapy.
Conclusions:
We developed a multivariate NTCP model for TUBE M6 after definitive (chemo) radiation, which can be used to predict TUBE M6. The four dosimetric variables in this prediction model can be used to optimize RT treatment planning aiming at prevention of tube feeding dependence. Purpose/Objective: To evaluate the prognostic significance of quantitative advanced imaging features derived from diagnostic CT images in HNSCC patients.We hypothesized that non-invasive imaging features of the tumor such as heterogeneity and shape extracted from already available CT images are prognostic for survival. Materials and Methods: Retrospective analysis of 150 patients with SCC of the head and neck (49 larynx and 101 oropharynx tumors) treated with radiotherapy alone or chemo-radiation with curative intent. All patients underwent a CT scan for treatment planning. The primary tumor was delineated by an experienced radiation oncologist on CT images. A set of 80 imaging features were automatically extracted from the tumor region on the CT scan, including 15 first order statistics, 33 textural features derived from gray level cooccurrence and rung-length matrices, 24 textural wavelet features and 7 tumor shape metrics (Fig 1) . For comparisons of CT features the Mann-Whitney U test was used to determine differences on overall survival. For TNM the Chi-square test was used. The Relieff algorithm was used to rank the CT features according to their importance attributes. Univariate and multivariate Cox proportional hazards models were used to compare the risk of death among patients. The performance of the model was evaluated with a 5-fold cross validated c-index. Table 1 for the top ranked features and for examples of features that were not significant. 39 CT features had significant differences among the overall survival groups. The combination of the top four parameters in the univariate analysis in a multivariate model rendered c-index of 0.77(CI, 0.69 -0.83). This c-index was better than the observed for TNM.
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Conclusions: This preliminary analysis shows that advanced textural and shape features are prognostic for survival in HNSCC patients. The multivariate model based on CT features and even individual CT features had a better discriminatory power than TNM for survival. Further analysis involves the association of CT features with locoregional tumor control and a sub-analysis per tumor anatomical location. External validation of these results will follow. Purpose/Objective: Treatment of head and neck squamous cell carcinomas (HNSCC) with radiotherapy and the epidermal growth factor (EGFR) inhibitor cetuximab has shown promising results, but is only effective in a fraction of HNSCC patients. Patient selection is based on EGFR expression as determined immunohistochemically, but this does not correlate with treatment response. The aim of this study was to develop and characterize the 111 In-cetuximab-F(ab') 2 tracer for imaging EGFR expression and to determine if tracer uptake correlates with response to EGFR-inhibitor treatment in HNSCC xenografts. Materials and Methods: The optimal protein dose and imaging timepoint was determined in athymic mice with s.c. FaDu xenografts. Subsequently, mice with HNSCC xenografts SCCNij202, 167, 185 and 153 were imaged with 111 In-cetuximab-F(ab') 2 . Results: The highest uptake of 111 In-cetuximab-F(ab') 2 in FaDu tuors was obtained at doses of 5 µg/mouse (13.50 ± 5.17 %ID/g). Due to the rapid blood clearance, tumor-to-blood ratios were high for 111 Incetuximab-F(ab') 2 (31.4 ± 3.8 at 24 h p.i.). MicroSPECT images showed preferential uptake in HNSCC xenografts; 3.1 ± 0.2 (SCCNij202), 2.8 ± 0.4 (SCCNij153), 2.0 ± 0.8 (SCCNij185), 2.0 ± 0.4 (SCCNij167) %ID/g. Overall tumor uptake of 111 In-cetuximab-F(ab') 2 correlated well with immuno-histochemical EGFR fractions (r=0.61, p<0.01). Growth delay experiments showed that SCCNij202 responded to cetuximab treatment whereas SCCNij167, SCCNij185 and SCCNij153 were nonresponders. Conclusions: 111 In-cetuximab-F(ab') 2 showed a clear heterogeneous distribution throughout the tumor. Tumor uptake correlated with treatment response in three out of four HNSCC xenografts. Purpose/Objective: Among head and neck cancer survivors many experience diminished quality of life owing to side effects following treatment; one of the predominant side effects is dysphagia, regardless of the treatment modality involved. The aim of this study was to investigate frequency, intensity and dose-volume characteristics for late dysphagia in head and neck cancer patients treated with curative IMRT. 
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